[Hopespringpcsg] FW: Prostatepedia Digest 1.28.2022

[Glen Tolhurst]

Hi all:
See below for many links to interesting articles.
Take care & stay well.
Glen

Sent from Mail for Windows

From: Prostatepedia

Subject: Prostatepedia Digest 1.28.2022


Sign up for Prostatepedia's Free Publications










New Links and Resources.

Prostatepedia's December 2021 Issue on Immuno-Oncology and Chemotherapy

Treatments driving a new Resistant Mutational Phenotype of Prostate Cancer:  Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio

ADT with Definitive Radiotherapy in Localized Prostate Cancer: Androgen Deprivation Therapy Use and Duration with Definitive Radiotherapy for Localised Prostate Cancer: An Individual Patient Data Meta-Analysis

Racial and Ethnic Disparities in Care: Racial/ethnic disparities in patient experiences with care and Gleason score at diagnosis of prostate cancer: a SEER-CAHPS study.

Acquired Resistance to Irradiation or Docetaxel: Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines.

Combination Therapy for mCRPC: Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.

Same-Day Discharge after Robotic Prostatectomy: Same-day-discharge Robot-assisted Radical Prostatectomy: An Annual Countrywide Analysis.

A new antibody-drug conjugate, MGC018, in mCRPC: Preliminary Results of MGC018, an anti B7-H3 Antibody Drug Conjugate in mCRPC – Eugene Shenderov

Germline DNA Damage Repair Alterations in Patients with Localized Prostate Cancer treated with Neoadjuvant ADT: Germline DNA Damage Repair Alterations in Patients with Localized Prostate Cancer Treated with Neoadjuvant Androgen Deprivation Therapy - Expert Commentary

CONTACT -02 Study of cabozantinib plus atezolizumab versus second novel hormone therapy in mCRPC: A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.

T2 Mapping MRI for Prostate Cancer Detection and Classification: Value of T2 Mapping MRI for Prostate Cancer Detection and Classification.

Video: Best Patient Selection for Radium-223 in mCRPC: Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone

Video: Pain efficacy of Radium-223 in mCRPC Patients with Symptomatic Bone Metastases: A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases – the REASSURE Trial – Celestia Higano

Video: Bone-Protecting Agents in mCRPC: The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen

Radioligand Therapy within 3 months of Radium-223: SNMMI 2021: Safety and Efficacy of Radioligand Therapy with 177lutetium-PSMA-617 Within 3 Months After 223Radium-Dichloride

Characterizing Bone Lesions with PET/CT: SNMMI 2021: Characterizing Bone Lesions in Prostate Cancer Patients with PET/CT Imaging

Prostate MRI Predicts Continence after Radical Prostatectomy: Prostate MRI predicts urinary continence after surgery

Depression and Newer Hormone Agents in Prostate Cancer: Newer Hormone Treatments for Prostate Cancer May Raise Risk of Depression

Risk Stratification of Localized Disease: ESOU 2022: State-of-the-art Lecture: Molecular Advances in Risk Stratification of Localized Prostate Cancer

Neoadjuvant Treatments Before Radical Prostatectomy:  ESOU 2022: Neoadjuvant Treatments before Radical Prostatectomy for High-Risk Prostate Cancer: Developments and Challenges

BiTE Mechanism (Immuno-Oncology) in Development for Advanced Prostate Cancer: Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor

Imaging: Reading and Reporting Results of a PSMA PET/CT for Staging Prostate Cancer:  Reading and Reporting a PSMA PET Scan for Staging Prostate Cancer - Andrea Farolfi

Should a TRUS-Guided Biopsy Remain Standard of Care?: Transrectal Ultrasound-Guided Biopsy Should Continue to Be a Standard of Care for The Detection of Prostate Cancer.

Active Surveillance for Intermediate-Risk Prostate Cancer: Active surveillance for intermediate-risk prostate cancer.

PSA Screening in the US According to Health Professional Counseling and Age, since the last set of USPSTF Recommendations: Prostate-Specific Antigen Screening According to Health Professional Counseling and Age in the United States.

Supportive Care Needs for Men with Prostate Cancer: Supportive care needs of men with prostate cancer: A systematic review update.

Video:  2022 NCNN Guidelines for Localized Disease: NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis

Video:  2022 NCCN Guidelines on Staging Evaluation and Imaging: NCCN Guidelines - Staging Evaluation and Imaging Approaches in Prostate Cancer – Christopher Wallis and Zachary Klaassen

Video: 2022 NCCN Guidelines on Advanced Prostate Cancer including Neuroendocrine Disease: NCCN Guidelines on Prostate Cancer Reviewing Advanced Prostate Cancer Neuroendocrine Disease, Bone and Visceral Metastases, and Treatment Sequencing – Christopher Wallis & Zachary Klaassen 



Reminders.

The 16th Annual Meeting of the National Alliance of State Prostate Cancer Coalitions (NASPCC) will take place on a new date: January 28-30, 2022. Here is the Final Agenda.

Please join NASPCC for a Webinar entitled “Overview of Prostate Cancer Imaging” With Thomas Hope, MD, Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco on Monday, February 7, 2022.

Merel Grey, president of NASPCC and Cal Ripken, Jr. Talk Prostate Cancer 

Jessie Myers-Schecter talks about her father, Snuffy Myers, and what it was like to be the daughter of a prostate cancer patient.  

NASPCC and CancerCare Online Prostate Cancer Patient Support Group

NASPCC Webinar Recordings Archive 























Copyright © 2022 Prostatepedia NASPCC, All rights reserved. 
You are receiving this email because you opted in via our website. 

Our mailing address is: 
Prostatepedia NASPCC
1999 Avenue of the Stars Ste 1100
Los Angeles, CA 90067-4618

Add us to your address book


. 






-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://artsservices.uwaterloo.ca/pipermail/hopespringpcsg/attachments/20220130/7751c988/attachment-0001.htm>